Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study
- 18 February 2004
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 92 (2) , 644-647
- https://doi.org/10.1016/j.ygyno.2003.11.023
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Ifosfamide and Doxorubicin in the Treatment of Advanced Leiomyosarcomas of the Uterus: A Gynecologic Oncology Group StudyGynecologic Oncology, 1996
- Preclinical characteristics of gemcitabineAnti-Cancer Drugs, 1995
- Aminothiadiazole in the Treatment of Advanced Leiomyosarcoma of the Uterine CorpusAmerican Journal of Clinical Oncology, 1995
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- Problematic Uterine Smooth Muscle NeoplasmsThe American Journal of Surgical Pathology, 1994
- Resection of pulmonary metastases from uterine sarcomasGynecologic Oncology, 1992
- A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterusInvestigational New Drugs, 1991
- Mitoxantrone in the Treatment of Advanced Uterine SarcomaAmerican Journal of Clinical Oncology, 1990
- Leiomyosarcoma of the uterus: Clinicopathologic study of 21 casesGynecologic Oncology, 1985
- Surgery for Pulmonary Metastasis: A 20-Year ExperienceThe Annals of Thoracic Surgery, 1984